We are live on ! Find out more
SLDB icon

Solid Biosciences

74 hedge funds and large institutions have $157M invested in Solid Biosciences in 2019 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more call options, than puts

Call options by funds: $6.18M | Put options by funds: $3M

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

4% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 23

1% less funds holding

Funds holding: 7574 (-1)

1.33% less ownership

Funds ownership: 4.55%3.22% (-1.3%)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

76% less capital invested

Capital invested by funds: $648M → $157M (-$491M)

Holders
74
Holders Change
-1
Holders Change %
-1.33%
% of All Funds
1.6%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
22
Increased
25
Reduced
15
Closed
23
Calls
$6.18M
Puts
$3M
Net Calls
+$3.18M
Net Calls Change
+$5.75M
Name Holding Trade Value Shares
Change
Change in
Stake
Marshall Wace
26
Marshall Wace
United Kingdom
$642K +$808K +3,227 +226%
MC
27
Matisse Capital
Oregon
$604K +$1.1M +4,380 New
Charles Schwab
28
Charles Schwab
California
$596K -$122K -485 -10%
Simplex Trading
29
Simplex Trading
Illinois
$585K +$921K +3,676 +649%
RSCM
30
Rock Springs Capital Management
Maryland
$552K +$16.8K +67 +2%
Morgan Stanley
31
Morgan Stanley
New York
$501K +$534K +2,130 +142%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$480K -$75.7K -302 -8%
State of Wisconsin Investment Board
33
State of Wisconsin Investment Board
Wisconsin
$470K +$641K +2,560 +302%
Voloridge Investment Management
34
Voloridge Investment Management
Florida
$410K +$745K +2,972 New
UBS Group
35
UBS Group
Switzerland
$407K -$1.22M -4,889 -62%
AIM
36
Assured Investment Management
New York
$379K +$688K +2,745 New
CM
37
Caption Management
Oklahoma
$354K +$643K +2,567 New
Goldman Sachs
38
Goldman Sachs
New York
$344K +$251K +1,003 +67%
Two Sigma Investments
39
Two Sigma Investments
New York
$340K +$617K +2,464 New
Acadian Asset Management
40
Acadian Asset Management
Massachusetts
$325K +$589K +2,352 New
AllianceBernstein
41
AllianceBernstein
Tennessee
$314K +$202K +806 +55%
CS
42
Credit Suisse
Switzerland
$290K +$388K +1,547 +277%
Swiss National Bank
43
Swiss National Bank
Switzerland
$259K
TA
44
Teachers Advisors
New York
$226K +$8.02K +32 +2%
SCA
45
Secor Capital Advisors
New York
$223K +$404K +1,614 New
Citigroup
46
Citigroup
New York
$207K -$812K -3,240 -68%
TCIM
47
TIAA CREF Investment Management
New York
$204K -$6.51K -26 -2%
Group One Trading
48
Group One Trading
Illinois
$202K +$348K +1,387 +1,874%
VF
49
Virtu Financial
New York
$186K +$338K +1,349 New
NIT
50
NumerixS Investment Technologies
British Columbia, Canada
$184K +$321K +1,280 New

SLDB Hedge Fund Activity: Q1 2019 in Review

74 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2019, worth a combined $157M — down 76% from $648M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of SLDB and 22 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 25 added.

The largest buyer was Artal Group, adding an estimated $11.7M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $105M sold.

  • 74 institutional investors held Solid Biosciences (SLDB) as of Q1 2019, down from 75 in Q4 2018.
  • Funds reported $157M of Solid Biosciences stock for Q1 2019, down 76% quarter-over-quarter.
  • 22 funds opened new Solid Biosciences positions in Q1 2019 and 23 closed out, a net change of -1 holder.
  • The largest Solid Biosciences buyer in Q1 2019 was Artal Group, an estimated $11.7M added.
  • The largest Solid Biosciences seller in Q1 2019 was Perceptive Advisors, an estimated $105M sold.

Based on aggregated 13F filings for Q1 2019.